Skip to Content

Regenxbio Inc RGNX

Morningstar Rating
$15.69 −0.42 (2.61%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RGNX is trading at a 40% discount.
Price
$16.06
Fair Value
$88.20
Uncertainty
Extreme
1-Star Price
$33.82
5-Star Price
$35.54
Economic Moat
Fqj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGNX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$16.11
Day Range
$15.3216.26
52-Week Range
$11.8928.80
Bid/Ask
$15.69 / $17.91
Market Cap
$769.48 Mil
Volume/Avg
574,896 / 766,064

Key Statistics

Price/Earnings (Normalized)
Price/Sales
7.81
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
344

Comparables

Valuation

Metric
RGNX
CBAY
PLRX
Price/Earnings (Normalized)
Price/Book Value
2.2812.651.63
Price/Sales
7.81111.01477.92
Price/Cash Flow
Price/Earnings
RGNX
CBAY
PLRX

Financial Strength

Metric
RGNX
CBAY
PLRX
Quick Ratio
2.3210.7017.43
Current Ratio
2.5710.9617.72
Interest Coverage
−37.42−5.27−145.34
Quick Ratio
RGNX
CBAY
PLRX

Profitability

Metric
RGNX
CBAY
PLRX
Return on Assets (Normalized)
−32.47%−30.06%−22.68%
Return on Equity (Normalized)
−54.67%−51.97%−24.50%
Return on Invested Capital (Normalized)
−43.35%−30.87%−28.46%
Return on Assets
RGNX
CBAY
PLRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXzmtrpwxrCvgz$550.4 Bil
VRTX
Vertex Pharmaceuticals IncXvbxglqrjGxmjvf$101.7 Bil
REGN
Regeneron Pharmaceuticals IncNwshqxplfPkxkqx$98.1 Bil
MRNA
Moderna IncSkxkxvtrYdgxd$39.1 Bil
ARGX
argenx SE ADRLwnpzyrHbj$21.7 Bil
BNTX
BioNTech SE ADRLrldbcfzpMwxs$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncYwwbrkcvVyqnd$18.4 Bil
BMRN
Biomarin Pharmaceutical IncTtnprzxgQzjqyr$17.1 Bil
RPRX
Royalty Pharma PLC Class ASffdtxmtGrqqzd$12.5 Bil
INCY
Incyte CorpPvsnqbxyJvszy$11.9 Bil

Sponsor Center